FDA’s ANDA Review Speeds Up In FY 2004
This article was originally published in The Pink Sheet Daily
With one month to go in fiscal year 2004, the Office of Generic Drugs has already approved more applications than in all of FY ’03. FDA attributes the improvements to better staff training and faster communication of deficiencies to sponsors.
You may also be interested in...
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.
Obamacare repeal has been replaced by rebrand as Trump administration plans to use ACA’s Medicare demonstration powers to send discount cards to seniors, one of a slew of health care announcements that include Rx importation, pre-existing conditions, insulin and EpiPens.
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.